Abstract
Heart plays a vital role in the human life survival. Now a days the global burden of heart problems is very high. There is very high mortality rate. So in this review we aimed to explore the cardioprotective drug dexrazoxane. Now, dexrazoxane has received approval for two different uses: avoiding tissue damage after anthracycline extravasation and preventing cardiotoxicity during anthracycline-based chemotherapy. Regardless of existing cardiac risk factors, the medication seems to provide cardiac protection. Dexrazoxane is a bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic properties, according to the prior study. So this study suggests that the dexrazoxane will play very important role in the treatment of cardiac problems.Keywords- Dexrazoxane, Anthracycline, Cardiotoxicity, Cardiovascular Disease, Chemotherapy, Doxorubicin
Publisher
International Consortium of Academic Professionals for Scientific Research
Reference52 articles.
1. Herman EH, Ferrans VJ. Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity. Semin Oncol. 1998;25(4 Suppl 10):15–21.
2. Langer SW, Sehested M, Jensen PB. Treatment of anthracycline extravasation with dexrazoxane. Clin Cancer Res. 2000;(9):3680–3686.
3. Langer SW, Sehested M, Jensen PB. Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice. Ann Oncol. 2001;12(3):405–410.
4. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB (2011) Anthracycline cardiotoxicity: from bench to bedside. NIH Public Access 26(22):3777–3784.
5. McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM (2017) Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther 31(1):63–75.